Because this medulloblastoma had an oncogenic mutation in BRCA2 (6174delT), we also tested its in vitro response to a PARP1 inhibitor, thought to induce synthetic lethality in BRCA2-mutated breast cancer (42). This evidence concerns the gene PARP1 and medulloblastoma.